Drugs / MT-6402
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04795713 | May 2021 → Oct 2024 | head and neck squamous cell carcinoma, non-small cell lung carcinoma | Molecular Templates, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-6402 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04795713 ↗ |
| Modality | Other / unclassified | “MT-6402 (an Engineered Toxin Body (ETB))” NCT04795713 ↗ |
| Route | Intravenous | “MT-6402 will be given as an intravenous (IV) infusion over 30 minutes” NCT04795713 ↗ |